NCT05700448View on ClinicalTrials.gov

Study of Sugemalimab (or Placebo) Plus PGemOx Regimen in Participants With Extranodal NK/T-Cell Lymphoma

PHASE3Not yet recruitingINTERVENTIONAL
Enrollment

150

Participants

Timeline

Start Date

December 31, 2025

Primary Completion Date

June 30, 2028

Study Completion Date

June 30, 2029

Conditions
Extranodal NK/T-cell Lymphoma
Interventions
BIOLOGICAL

Sugemalimab

IV infusion

DRUG

Placebo

IV infusion

DRUG

Pegaspargase

Intramuscular injection

DRUG

Gemcitabine

IV infusion

DRUG

Oxaliplatin

IV infusion

Sponsors
All Listed Sponsors
lead

CStone Pharmaceuticals

INDUSTRY